Literature DB >> 2994922

The influence of lithium chloride on experimental autoimmune thyroid disease.

R A Hassman, J H Lazarus, C Dieguez, A P Weetman, R Hall, A M McGregor.   

Abstract

Lithium administration is known to be associated with the development of thyroid dysfunction; it also exerts an effect on the immune system. The effect of lithium on experimental autoimmune thyroid disease was studied in female August rats. Following immunization with rat thyroglobulin in Freund's complete adjuvant, lithium chloride was administered i.p. for 30 days to four groups at varying stages of the disease. Control animals received i.p. saline. Anti-thyroglobulin antibody levels (measured by ELISA) were significantly increased in rats given lithium immediately post-immunization (group B) compared to control animals (661 +/- 42 OD vs 448 +/- 68; mean +/- s.e., P less than 0.02). In contrast, animals which received lithium during the spontaneous resolution of the disease (group D) showed a significant fall in anti-TG antibody compared to controls (99 +/- 15 vs 27 +/- 15; P less than 0.001). Anti-TG antibody levels remained undetectable in animals which received lithium but were not immunized. The splenic T cell blastogenic response (as measured following phytohaemagglutinin stimulation) was significantly increased in rats receiving lithium prior to and during immunization (group A) (stimulation index 63.4 +/- 6.9 vs 10.2 +/- 2.4; P less than 0.001). Spontaneous cell proliferation of splenic lymphocytes was decreased in two lithium treated groups (group A P less than 0.005, group C P less than 0.05). There was no alteration in splenic weight or the degree of thyroid lymphocytic infiltration in any of the treated group. Lithium exerted both positive and negative influences on the immune system in rats immunized with thyroglobulin in adjuvant but did not induce autoantibody production in normal rats.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994922      PMCID: PMC1577238     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Antinuclear antibodies in patients on lithium carbonate.

Authors:  A P Presley; A Kahn; N Williamson
Journal:  Br Med J       Date:  1976-07-31

2.  Enhancement of lymphocyte and macrophage function in vitro by lithium chloride.

Authors:  L Shenkman; W Borkowsky; R S Holzman; B Shopsin
Journal:  Clin Immunol Immunopathol       Date:  1978-06

Review 3.  Mechanisms of lithium action.

Authors:  I Singer; D Rotenberg
Journal:  N Engl J Med       Date:  1973-08-02       Impact factor: 91.245

4.  Endocrine exophthalmos during lithium therapy of manic-depressive disease.

Authors:  R L Segal; S Rosenblatt; I Eliasoph
Journal:  N Engl J Med       Date:  1973-07-19       Impact factor: 91.245

5.  Serum thyrotropin and thyroxine concentrations in patients recieving lithium carbonate.

Authors:  C H Emerson; W L Dysno; R D Utiger
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

6.  Lithium therapy and hypothyroidism.

Authors:  C R Birch; D J Jolley; G G Hay; I W Dymock
Journal:  Br Med J       Date:  1972-10-28

7.  On the prevalence, diagnosis and management of lithium-induced hypothyroidism in psychiatric patients.

Authors:  G Lindstedt; L A Nilsson; J Wålinder; A Skott; R Ohman
Journal:  Br J Psychiatry       Date:  1977-05       Impact factor: 9.319

8.  Effect of lithium on hypothalamic-pituitary-thyroid function in patients with affective disorders.

Authors:  D G McLarty; J H O'Boyle; C A Spencer; J G Ratcliffe
Journal:  Br Med J       Date:  1975-09-13

9.  Sensitivity to lithium in treated Graves' disease: effects on serum T4, T3 and reverse T3.

Authors:  K D Burman; R C Dimond; J M Earll; F D Wright; L Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

10.  Antinuclear antibodies in psychiatric illness: their relationship to diagnosis and drug treatment.

Authors:  E C Johnstone; K Whaley
Journal:  Br Med J       Date:  1975-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.